Question-and-Answer SessionSean McCarthyChairman & CEO Yes. Thanks, Ross, and thanks for having us at the conference today. Real pleasure to be here. So CytomX is an oncology-focused biologics company, developing a platform technology and a pipeline around that platform called the Probody therapeutic platform. And this is a unique antibody masking strategy that we pioneered. In fact, I refer to CytomX as the original masking company. We got this whole field going really going back as long as 15 years. And t ...

公司业务定位 - 专注于肿瘤学领域的生物制剂开发 拥有Probody治疗平台技术 [1] - 作为抗体掩蔽技术的原创者 开创该领域研究已达15年 [1] 核心技术优势 - 独创抗体掩蔽策略 可改善高效抗癌药物的治疗窗口 [1] - 技术适用于抗体药物偶联物(ADC)和T细胞衔接器等强效制剂 [1] 研发管线进展 - 临床阶段拥有两个重点项目：靶向EpCAM的掩蔽ADC药物CX-2051 [1] - 同步开发掩蔽型干扰素α-2b项目CX-801 [1] - 项目推进取得重大进展 [1]